



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299 THAMBU CHETTY STREET, CHENNAI - 600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com CIN: L24294
TN1995PLCO30698

BPL SE CS OMS 01/2023.

December 25, 2023.

To,

Listing Department, BSE Limited, P J Towers, Dalal Street, Mumbai – 400001.	Listing Department, National Stock Exchange of India, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051.
Security Code: 532989 Security ID: BAFNAPHARM	Symbol: BAFNAPH Series: EQ.

Dear Sir/Madam,

Subject: Filing of report under Regulation 7(2)(b) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended (“SEBI Insider Trading Regulations”).

We hereby submit the attached disclosure received under Regulation 7(2)(a) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, from SRJR Lifesciences LLP, one of the Promoters of Bafna Pharmaceuticals Limited (“the Company”), regarding disposal of the Equity Shares of the Company.

This submission is pursuant to Regulation 7(2)(b) of SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended.

This disclosure will also be made available on the website of the Company www.bafnapharma.com.

Kindly take the above intimation on record.

Thank you,

Yours faithfully,
For Bafna Pharmaceuticals Limited,

(Vishnu V. Kuppa)
Company Secretary & Compliance Officer.

Encl.: As above.

SRJR LIFESCIENCES LLP

Reg Address: ilabs Center, Building No.3, Plot No .18, Software Units Layout, Madhapur, Hyderabad,
Telangana – 500081
LLP IN: AAR-4517

Date: 23RD December, 2023

To
Mr. Melagiri Sridhar (CFO),
Bafna Pharmaceuticals Limited
299, Thambu Chetty Street
Madras, Tamil Nadu - 600 001

Dear Sir,

Sub:- Continual Disclosure under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015

ISIN: INE878I01022

As per Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, we, SRJR Lifesciences LLP being promoter of **Bafna Pharmaceuticals Limited (“the Company”)**, hereby declare and confirm that we have disposed of 30,000 (Thirty Thousand) shares held by us in the Company on 22nd December 2023, for a total value of Rs. 29,63,350.70/-. (Rupees Twenty-Nine Lakhs Sixty-Three Thousand Three Hundred and Fifty and Seventy Paise Only).

In this regard, please find attached herewith requisite disclosure as per Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

We request you to take on record the above information and take necessary action on the same.

Thanking You,

For and on behalf of **SRJR LIFESCIENCES LLP**



Upendar Mekala Reddy
Designated Partner
DIN: 08898174



FORM C

SEBI (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7 (2) read with Regulation 6(2) – Continual disclosure]

Name of the company: **BAFNA PHARMACEUTICALS LIMITED**
ISIN of the company: **INE878101022**

Details of change in holding of Securities of Promoter, Employee or Director of a listed company and other such persons as mentioned in Regulation 6(2).

Name, PAN, CIN/DIN, & Address with contact nos.	Category of Person (Promoters/ KMP / Director / Immediate relative to others etc.)	Securities held prior to acquisition/disposal		Securities acquired/Disposed			Securities held post acquisition/disposal		Date of allotment/Date of acquisition / sale of shares specify		Date of intimation to company	Mode of acquisition / disposal (on market/public/ rights/preferential offer / off market/ Inter-setransfer, ESOPs etc.)	
		Type of security (For eg. Shares, Warrants, Convertible Debentures etc.)	No. and % of share holding	Type of security (For eg. Shares, Warrants, Convertible Debentures etc.)	No.	Value	Transaction Type (Buy/Sale/Pledge / Revoke/ Invoke)	Type of security (For eg. Shares, Warrants, Convertible Debentures etc.)	No. and % of shareholding	From			To
1 SRJR LIFESCIENCES LLP PAN: AECFS1208Q LLPIN: AAR-4517 ADDRESS: ilabs Centre, Building No. III, No. 18 Software Units Layout, Madhapur Hyderabad Telangana 500081 CONTACT NO. 040- 40484444	2 Promoter	3 Shares	4 2,08,89,493 Percentage – 88.30 %	5 Shares	6 30,000	7 29,63,350.70	8 Sale	9 Shares	10 2,08,59,493 Percentage – 88.18%	11 22 nd December, 2023	12 22 nd December, 2023	13 23 rd December, 2023	14 On Market

Note: "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Details of trading in derivatives of the company by Promoter, Employee or Director of a listed company and others such persons as mentioned in Regulation 6(2) – N A

Type of contract	Contract specifications	Trading in derivatives (Specify type of contract, Futures or Options etc)				Exchange on which the trade was executed
		Buy		Sell		
		Notional Value	Number of units (contracts * lot size)	Notional Value	Number of units (contracts * lot size)	
15	16	17	18	19	20	21

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

Name & Signature: **Upendar Mekala Reddy**



UP
2
Upendar Reddy

Designation: **Designated Partner**
Date: 23rd December, 2023
Place: Hyderabad
